MIRM News and Press, Mirum Pharmaceuticals Inc. From 12/01/25

Proof-of-concept study underway for investigational oral therapy in Fragile X syndrome; top-line data from Phase 2 expected in 2027 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Pha...

New data reinforce Mirum’s commitment to advancing therapies and improving the lives of patients across diverse rare liver diseases. Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that multiple presentations featuring data from its LIV...

2025-11-04 18:57:00 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. (MIRM) Q3 2025 Earnings Call Transcript Mirum Pharmaceuticals, Inc. (MIRM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript Mirum Pharmaceuticals: Q2 Result...

2025-11-04 18:56:24 ET Mirum Pharmaceuticals, Inc. (MIRM) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Mirum Pharmaceuticals, Inc. (MIRM) Q3 2025 Earnings Call Transcript

2025-11-04 16:15:37 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. (MIRM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript Mirum Pharmaceuticals: Q2 Results Continue To Show Positive Momentum Mirum Pharmaceuticals, Inc. (MI...

- Third quarter 2025 total revenue of $133 million - 2025 revenue guidance updated to $500 to $510 million - Phase 2b VISTAS topline data expected second quarter of 2026 - Conference call to provide business updates today, November 4 at 1:30 p.m. PT / 4:30 p.m. ET Mirum Phar...

2025-11-04 10:00:00 ET Major earnings expected after the bell on Tuesday include: Advanced Micro Devices ( AMD ) Super Micro Computer ( SMCI ) Amgen ( AMGN ) Arista Networks ( ANET ) Pinterest ( PINS ) Read the full article on Seeking Alpha ...

Advanced Energy Industries Inc. (AEIS) is expected to report $1.16 for Q3 2025 Neuropace Inc. (NPCE) is expected to report $-0.2 for Q3 2025 Oportun Financial Corporation (OPRT) is expected to report $0.2 for Q3 2025 trivago N.V. (TRVG) is expected to report $0.07 for Q3 2025 Alle...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report third quarter 2025 financial results on November 4, 2025. Mirum will also host a conference call to discuss the third quarter 2025 financial results and recent corporate progress. Conference call details: Tuesday...

2025-09-24 14:03:51 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. (MIRM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript Mirum Pharmaceuticals: Q2 Results Continue To Show Positive Momentum Mirum Pharmaceuticals, Inc. (MI...